


Fosun Pharma inks deal with Medidata

23 August 2017 | News

Fosun Pharma is implementing Medidata Rave, a unified EDC and CDMS solution for capturing, managing and reporting patient data



In a bid to bring operational efficiency and improve data management, Chinese healthcare group Fosun Pharma has adopted the Medidata Clinical Cloud platform. Fosun announced an enterprise agreement with Medidata the leading global provider of cloud-based technology and data analytics for clinical research.

Fosun Pharma is implementing Medidata Rave, a unified EDC and CDMS solution for capturing, managing and reporting patient data, across its generics development pipeline, accelerating treatments in such therapeutic areas as cardiovascular, oncology, anti-infection and central nervous system (CNS).

The Chinese clinical R&D company is also leveraging Rave Study Design and Build Essentials (SDBE) training. Taught on RaveX—the latest version of Rave—SDBE will equip Fosun Pharma's study teams with the fundamentals required to develop and update electronic Case Report Forms (eCRFs), ultimately optimizing study implementation and ensuring trial timelines are met.

Edwin Ng, Medidata's vice president of field operations, APeJ (Asia Pacific except Japan), said, "We are proud to be Fosun Pharma's cloud-based, clinical technology platform of choice and a key addition to its roster of partners. We look forward to powering Fosun Pharma's clinical studies with Medidata's flexible, cutting-edge technology as they strive to become a first-class enterprise in the global healthcare market and a key player in the bioequivalence space."

Earlier this year, another Chinese company BeiGene had also announced collaboration with Medidata for its electronic data capture platform called Rave. Medidata recently reported a strong second quarter with quarterly revenues reaching \$137.4 million, representing a 20% year-on-year jump.

The increase was driven by continued demand for its platforms, Medidata Chairman and CEO Tarek Sherif told investors and

analysts during a conference call on July 18. Patient Cloud performed especially well, as incremental bookings quadrupled in the first half of 2017 compared to last year, reported Fierce Pharma.

Medidata has been expanding its presence in Asia, with offices in Tokyo, Seoul, Beijing, Shanghai and Singapore. Besides biopharma companies like BeiGene and Henlius Biotech, some of its partners in China also include CROs WuXi AppTec and R&G PharmaStudies, and research institutions like Peking University Clinical Research Institute.